Astrocytoma, Grade IV
Conditions
Keywords
Astrocytoma, Grade IV, Glioblastoma, Glioblastoma IDH wildtype, Astrocytoma IDH mutant, Glioblastoma IDH mutant, High-grade glioma
Brief summary
This Clinical study is framed in the ALBATROSS Project: Clinically validated decision support system based on pixel level Artificial Intelligent models for deciding treatment in glioblastoma. The prospective multicenter international dataset compiled during the ALBATROSS project will include a cohort up to 300 new patients diagnosed with GB after June 1, 2020. Longitudinal images (T1, T2, T1c, FLAIR, PWI-DSC and DWI at least), complete molecular profiling, primary and secondary lines of treatment and clinical conditions will be included for each patient.
Detailed description
The Hypothesis under study in this project is: Therapeutic decision making during clinical management of patients with glioblastoma may benefit from delineating functional habitats at pixel level relative to growth, proliferation, infiltration and angiogenesis The Overall Scientific Objectives of the research proposal are to: OSO1. Delineate functional habitats from multiparametric MRI relative to the growth, proliferation, infiltration and angiogenesis at the enhanced tumor and infiltrated peripheral edema OSO2. Demonstrate that functional habitats at enhanced tumors and infiltrated peripheral edema show structural, cellular and molecular differences related to the heterogeneity of the tumor region and are compatible with mathematical models of glioma growth and infiltration OSO3. Determine the in-vivo molecular sub-type of patients with glioblastoma from image biomarkers in functional habitats OSO4. Identify groups of patients with glioblastoma presenting positive therapeutic response in terms of longer survival using image biomarkers from functional habitats OSO5. Position ONCOhabitats as a clinical decision support system for the management of patients with glioblastoma
Interventions
None listed
Sponsors
Oslo University Hospital
Azienda Ospedaliero-Universitaria di Parma
Hospital Clinic of Barcelona
Hospital Vall d'Hebron
Hospital de la Ribera
Hospital de Manises
Centre Hospitalier Universitaire de Liege
Juan M Garcia-Gomez
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with astrocytoma grade IV WHO with histopathological/genetic confirmation who undergo the Stupp treatment * Age \> 18 years at diagnosis * Patients with access to complete preoperative, postoperative and follow up MRI studies, including: * Pre gadolinium T1-weighted MRI * Post gadolinium T1-wighted MRI * T2-weighted MRI * Fluid-Attenuated Inversion Recovery (FLAIR) * Dynamic Susceptibility Contrast (DSC) T2\*-weighted perfusion sequences * Diffusion Weighted Imaging (DWI) * Patients who undergo surgery with the possibility to collect samples from different regions of the tumor
Exclusion criteria
* Patient with congestive heart failure within 6 months prior to study entry (New York Heart Association \>= Grade 3) * Uncontrolled or significant cardiovascular disease, including: * Myocardial infarction and transient ischemic attack or stroke within 6 months prior to enrollment * Uncontrolled angina within 6 months * Diagnosed or suspected congenital long QT syndrome * Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes) * Clinically significant abnormality on electrocardiogram (ECG) * Pulmonary disease including or greater than grade 2 dyspnea or laryngeal edema, grade 3 pulmonary edema or pulmonary hypertension according to CTCAE 4.03
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | From date of inclusion (date of first MRI) until the date of death, assessed up to 48 months | Overall Survival is defined as the time from the first presurgical MRI is taken to the patient (MR0) to death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | From date of inclusion (date of first MRI) until the date of documented tumor progression, assessed up to 48 months | Progression Free Survival is defined as the time from the first presurgical MRI is taken to the patient to the detection of tumor relapse |
Countries
Spain
Outcome results
None listed